Coherently, studies on patients with MDD undergoing ECT have demonstrated an increase in peripheral BDNF levels, indicating this neurotrophin as an important mediator of the effects of this therapy [24,48,49]. The gene discussed is BDNF; the disease is major depressive disorder.